Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662963 | 0.87 | NOS3 (0.39) | NOS3NOS2BACE1ALDH1A1PTGS2 | |
| SCHEMBL6675970 | 0.85 | NOS3 (0.42) | NOS3NOS2ALDH1A1CYP3A4MEN1 | |
| SCHEMBL19250366 | 0.80 | ESR1 (0.35) | NOS3NOS2CYP3A4ESR1 | |
| SCHEMBL20637613 | 0.79 | NOS3 (0.47) | NOS3NOS2BACE1ALDH1A1PTGS2 | |
| SCHEMBL6465582 | 0.74 | NOS3 (0.44) | NOS3NOS2PTGS2ESR1KDM5B | |
| SCHEMBL6464978 | 0.74 | NOS2 (0.70) | NOS3NOS2ESR1 | |
| SCHEMBL13313441 | 0.74 | NOS3 (0.40) | NOS3NOS2ESR1ESR2KDM5B | |
| SCHEMBL5898465 | 0.74 | NOS3 (0.40) | NOS3NOS2ESR1KDM5BCYP1A2 | |
| SCHEMBL16477773 | 0.73 | CA12 (0.51) | ALDH1A1CYP3A4MEN1KMT2AESR1 | |
| SCHEMBL11375661 | 0.73 | HSD17B1 (0.52) | CYP3A4ESR1ESR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109249151-B | Solder composition and electronic substrate | 株式会社田村制作所 | 2021-12-14 | — | — | CN | claimed |
| US-10906137-B2 | Solder composition and electronic board | TAMURA CORPORATION (JP) | 2021-02-02 | — | — | US | claimed |
| CN-109249151-B | Solder composition and electronic substrate | 株式会社田村制作所 | 2021-12-14 | — | — | CN | disclosed |
| US-10906137-B2 | Solder composition and electronic board | TAMURA CORPORATION (JP) | 2021-02-02 | — | — | US | disclosed |
| US-20190015937-A1 | SOLDER COMPOSITION AND ELECTRONIC BOARD | TAMURA CORPORATION (JP) | 2019-01-17 | — | — | US | disclosed |
| WO-2016022644-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2011159920-A1 | [5,6]-DIHYDRO-2H-PYRAN-2-ONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | RNASE1, GTF3C4, POLRMT | NOS3 1814/4885NOS2 3396/4885BACE1 4393/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | NOS3 1814/4885NOS2 3396/4885BACE1 4393/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | NOS3 1814/4885NOS2 3396/4885BACE1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.